Fulcrum Therapeutics (FULC) News Today → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free FULC Stock Alerts $7.85 +0.20 (+2.61%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 29, 2024 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Buy" from BrokeragesMay 24, 2024 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) to Post FY2024 Earnings of ($0.78) Per Share, Cantor Fitzgerald ForecastsMay 24, 2024 | americanbankingnews.comFinancial Survey: Fulcrum Therapeutics (NASDAQ:FULC) & Cytokinetics (NASDAQ:CYTK)May 23, 2024 | marketbeat.comFulcrum Therapeutics, Inc. Expected to Earn FY2024 Earnings of ($0.78) Per Share (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for shares of Fulcrum Therapeutics in a research note issued to investors on Monday, May 20th. Cantor Fitzgerald analyst K. Kluska anticipates that the companyMay 21, 2024 | marketbeat.comInvestors Purchase High Volume of Fulcrum Therapeutics Call Options (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw unusually large options trading on Tuesday. Investors acquired 9,544 call options on the stock. This is an increase of approximately 867% compared to the average daily volume of 987 call options.May 21, 2024 | msn.comCantor Fitzgerald Initiates Coverage of Fulcrum Therapeutics (FULC) with Overweight RecommendationMay 20, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Research Coverage Started at Cantor FitzgeraldCantor Fitzgerald initiated coverage on Fulcrum Therapeutics in a report on Monday. They set an "overweight" rating and a $23.00 target price for the company.May 16, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Fulcrum Therapeutics Amid Sanofi Partnership and Promising Drug ProspectsMay 16, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Expected to Earn Q2 2024 Earnings of ($0.43) Per ShareFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2024 earnings estimates for Fulcrum Therapeutics in a research report issued on Tuesday, May 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.4May 15, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Trading 7.5% Higher Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Up 7.5%May 15, 2024 | marketbeat.comFulcrum Therapeutics, Inc. to Post FY2028 Earnings of $0.51 Per Share, HC Wainwright Forecasts (NASDAQ:FULC)Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Investment analysts at HC Wainwright dropped their FY2028 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research report issued to clients and investors on Tuesday, May 14th. HC Wainwright analyst A. Fein now expMay 14, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Fulcrum Therapeutics (FULC)May 14, 2024 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2024 Earnings Call TranscriptMay 14, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest Up 18.6% in AprilFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) saw a large increase in short interest in the month of April. As of April 30th, there was short interest totalling 3,000,000 shares, an increase of 18.6% from the April 15th total of 2,530,000 shares. Based on an average trading volume of 598,700 shares, the short-interest ratio is presently 5.0 days.May 14, 2024 | finance.yahoo.comWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?May 14, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) PT Lowered to $14.00Oppenheimer reduced their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday.May 14, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $17.00 target price on shares of Fulcrum Therapeutics in a research report on Tuesday.May 14, 2024 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 13, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded by The Goldman Sachs Group to BuyThe Goldman Sachs Group raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and set a $15.00 target price for the company in a research report on Monday.May 13, 2024 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | finance.yahoo.comFulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...May 13, 2024 | globenewswire.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024May 13, 2024 | globenewswire.comFulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular DystrophyMay 12, 2024 | markets.businessinsider.comHere's what to expect from Fulcrum Therapeutics's earningsMay 9, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate in Upcoming May ConferencesMay 8, 2024 | finance.yahoo.comFulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet NeurologyMay 7, 2024 | marketbeat.comFulcrum Therapeutics (FULC) Set to Announce Earnings on MondayFulcrum Therapeutics (NASDAQ:FULC) will be releasing earnings before the market opens on Monday, May 13, Zacks reports.May 6, 2024 | globenewswire.comFulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ETMay 1, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Short Interest UpdateFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 2,530,000 shares, a growth of 11.9% from the March 31st total of 2,260,000 shares. Based on an average trading volume of 632,000 shares, the short-interest ratio is currently 4.0 days.May 1, 2024 | finance.yahoo.comEpsilogen Appoints Ashley Nagle as Chief Business Officer and Peter Finan as Non-Executive Chairman as Part of Broader Company ExpansionApril 30, 2024 | marketbeat.com256,888 Shares in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Bought by abrdn plcabrdn plc purchased a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 256,888 shares of the company's stock, valued at approximately $1,7April 16, 2024 | marketbeat.comShort Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Drops By 5.4%Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 2,260,000 shares, a decrease of 5.4% from the March 15th total of 2,390,000 shares. Based on an average daily volume of 668,800 shares, the short-interest ratio is currently 3.4 days.April 15, 2024 | investorplace.comBiotech on a Budget: 7 Stocks Under $10 With Huge PotentialApril 9, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Moderate Buy" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating onApril 3, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.6% Fulcrum Therapeutics (NASDAQ:FULC) Shares Down 4.6%March 28, 2024 | finance.yahoo.comFulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy SymposiumMarch 25, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Down 6.2% Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 6.2%March 22, 2024 | globenewswire.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 20, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down to $10.10Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Down to $10.10March 19, 2024 | finance.yahoo.comFULC Apr 2024 9.000 putMarch 19, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)March 18, 2024 | finanznachrichten.deFulcrum Therapeutics, Inc.: Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 18, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.6%Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 4.6%March 18, 2024 | msn.comFulcrum Therapeutics appoints Patrick Horn as permanent Chief Medical OfficerMarch 18, 2024 | globenewswire.comFulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical OfficerMarch 17, 2024 | marketbeat.comHudson Bay Capital Management LP Buys New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Hudson Bay Capital Management LP bought a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 196,488 shares of the company's stock, valued at approxMarch 15, 2024 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned an average rating of "Moderate Buy" from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating oMarch 13, 2024 | tmcnet.comFulcrum Deepens Collaboration with Esri, Recognized as Bronze PartnerMarch 13, 2024 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $10.91Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap Up to $10.91March 11, 2024 | insidertrades.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) VP Sells $57,240.48 in Stock Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Biotech's Best Kept Secret: Potential 46,751% Gain (Ad)The world's #1 biotech investor has been praising this stock since it was just $18.56. Even though it's rocketed 266% this year, he's now recommending a different biotech entirely! Get the name of the stock here >>> FULC Media Mentions By Week FULC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼1.070.77▲Average Medical News Sentiment FULC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼23▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ORTX News Today SGMO News Today BLUE News Today KZR News Today AGIO News Today PTGX News Today ZLAB News Today KROS News Today GPCR News Today SNDX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking $16T Elon Musk Crypto LeakCrypto 101 MediaWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsWrite this ticker symbol down…StocksToTradeBiden replacement revealed?Paradigm PressThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.